At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 236 enrolled
Drug / intervention
CF101drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Dry Eye Disease
In Brief
A Phase 3 clinical trial evaluating CF101 for Keratoconjunctivitis Sicca. Completed, enrolled 236 participants across 1 site.
Detailed Summary
Eligible patients with dry eye will be treated with CF101 or placebo twice daily for 24 weeks. Disease activity will be assessed using evaluations of ocular surface integrity, tear production, and patient symptoms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKeratoconjunctivitis Sicca
CountriesIsrael
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2010
Enrollment StartJul 2011
Primary CompletionNov 2013
Study CompletionDec 2013
TodayJul 2026
First PostedNov 5, 2010
Enrollment StartJul 1, 2011
Primary CompletionNov 1, 2013
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.7 years ago
Interventions
CF101drug
orally q12h